Oncolytic reovirus
OwnerMaya Shmulevitz, Adil Mohamed +2inventors
InventorsMaya Shmulevitz, Adil Mohamed, Mary Hitt, Wan Kong Yip
Life of this patent
Estimating the term…
Abstract
The present disclosure provides modified reovirus with improved characteristics, including improved oncolytic activity. Reoviruses provided herein include resortant viruses as well as viruses expressing mutated proteins. Methods of using such modified reovirus for inducing cancer cell lysis as well as treatment of cancer are disclosed. Also provided are methods tailored for induction of a desired cytokine profile in conjunction with, e.g., methods of inducing cancer cell oncolysis.
Claims12
A T3DPL reovirus genetically modified to express a T3DPL reovirus λ2 protein comprising a mutation in a FLAP domain, wherein said mutation comprises a substitution of isoleucine at position 1274 in SEQ ID NO:
- 9, wherein the substitution is I1274M or I1274M.
Dependencies are inferred from the claim text.